Open AccessManifestations of COVID-19 infection in patients with Multiple sclerosis and Neuromyelitis optica
Author(s) -
Julia Crivelaro,
Ana Cláudia Piccolo,
Ana Carolina Amaral de Andrade,
Henrique Aguera,
Julia Dallana,
Amélia Zambon
Publication year - 2021
Language(s) - English
Resource type - Conference proceedings
DOI - 10.5327/1516-3180.216
Subject(s) - medicine , neuromyelitis optica , multiple sclerosis , comorbidity , serology , covid-19 , retrospective cohort study , spectrum disorder , outpatient clinic , outbreak , pediatrics , disease , antibody , immunology , pathology , infectious disease (medical specialty) , psychiatry
The pandemic caused by the new SARS-Cov2 coronavirus, raised concerns about the impact of COVID19 on patients with autoimmune diseases such as Multiple Sclerosis (MS) and the Neuromyelitis Optic Spectrum (ENMO), undergoing treatment with immunosuppressive, immunomodulatory and monoclonal antibodies. Objective: To analyze the clinical evolution of COVID19 in patients diagnosed with MS and ENMO. Methods: retrospective study including patients diagnosed with MS and ENMO at the demyelinating disease outpatient clinic at Hospital Santa Marcelina, who were diagnosed with COVID 19 from April 2020 to April 2021. Results: 27 patients were included, with a mean age of ± 41.74 years (21 - 63 years), four with ENMO (14.81%) and twenty-three (85.19%) with Multiple Sclerosis (91.3 % with Sending MS - Recurrent (RR), and 8.7% with Secondary MS - Progressive (SP)). No patient had an outbreak, and only one (3.7%) had a pseudo-outbreak, 21 patients (77.8%) had nasal / oropharyngeal swab with positive RT-PCR for SARS-Cov2, 02 patients had negative RT-PCR and positive IgG (7 , 4%), and 04 patients (14.8%) with RT-PCR and serology not performed (presumed diagnosis of COVID19). Twenty patients (74%) had mild symptoms of COVID19, two (7.5%) with moderate symptoms, and another five (18.5%) with severe symptoms (admitted to the ICU), none of whom died. Four patients (14.8%) had an altered chest tomography (ground-glass pattern). Seven patients (34%) had some clinical or psychiatric comorbidity. Conclusion: The manifestations and complications of COVID-19 in this group of patients were similar to those presented by the general population.